TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fidelity of intervention implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal pro–B-type natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of test preparations to reference preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of fluoxetine after stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unplanned removal of PIVCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of phlebitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of blood-stream infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: freedom from migraine-related head pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between physicians’ and patients’ answers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHIP‐14K score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean infarct size at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall exercise accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of oxygen (pO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum levels of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of NRT patch and lozenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prefrontal brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: adverse reactions post vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: severity of symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: D-dimer elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Core temperature rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference of patients to be treated with antivirals rather than be randomized
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Belief among ZEDS investigators that antivirals are effective
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in spontaneous speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient and caregiver global impression of change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in apathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uptake of postpartum LARC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Overweight/obesity prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of IGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IGD criteria met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of families in treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: biochemically validated abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants reporting a behavioral change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of post-stroke depression (PSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean volume gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to severe avoidable patient harm
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative length of stay (LOS)
Endpoint domain: Resource use
Primary endpoint: Level of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk factors improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective reactions to nicotine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body average interface pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PedsQL as a primary outcome for children with hemorrhagic brain injuries
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intracranial hemorrhage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood product transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of asymptomatic DVT
Endpoint domain: Adverse events/effects
Primary endpoint: Change in leg volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TUG scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FV intake at the 50th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FV intake at the 25th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma 18-hydroxyeicosapentaenoic acid (18-HEPE) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma arachidonic acid (AA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma urea and creatinine elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: tubular injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of lymphopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nadir-PLC/pre-PLC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Interbeat period measured by the RR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Pa CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite of fatal CVD or new hospitalizations for non-fatal myocardial infarction, stroke, heart failure, coronary artery bypass graft, or percutaneous coronary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: navigation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of obturator jerk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in management decisions
Endpoint domain: Delivery of care
Primary endpoint: Mean absolute change in MFIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (dizziness and sedation)
Endpoint domain: Adverse events/effects
Primary endpoint: Dental age delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASM prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total error in ASM prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass correlation coefficient (ICC) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NOSHT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tinnitus severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: better competencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum TxB2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: symptom dyspepsia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sense of control postpartum
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: blood pressure-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NTIRE incidence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic lung allograft dysfunction-free survival
Endpoint domain: Mortality/survival
Primary endpoint: mean plugging rate of dentinal tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach pH 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage decrease from baseline in integrated gastric acidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: volume of total drainage in 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: length of walking distance during 6-min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sIL-4R levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sVEGF-R3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a ≥ 50% response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bipolar Disorder (BD) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bipolar Disorder type 1 risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of local failure
Endpoint domain: Mortality/survival
Primary endpoint: Reirradiation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VAS score post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in FEV1/FVC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: suture time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stitch out time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for postoperative antiglaucoma medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visually significant cataract and bleb related complications
Endpoint domain: Adverse events/effects
Primary endpoint: highest visual analog scale in the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Glottic Opening score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cormack Lehane grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective intubation difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual skin smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 3-month PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: thirst and mouth dryness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of exercise performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of exercise performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at 45 days
Endpoint domain: Mortality/survival
Primary endpoint: ICU admission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time on a ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with hypertensive care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrent presence of P. aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: GPQI-16 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage spending on targeted foods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Schirmer's test-I values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSDI score (Ocular Surface Disease Index)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in test completion percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in male alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS part III total motor symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Material and emergency costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subjective alcohol craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Role limitations due to physical function
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cooling duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneoconjunctival staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) rate at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: rates of hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: S mutans expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag time before initiation of CCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CCs with correct depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological health outcomes (BDI, POMS, PAID, D-39)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of posttraumatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of riociguat
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic efficiency of models for pelvic lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: USSQ urinary symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post biopsy infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in students' perceptions of self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in actual performance of core competencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal urinary CTX levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in PMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in PML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: longitudinal childhood ALRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: median nonmenstrual pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median menstrual pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life improvements (EHP-30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: COVID‐19–related return visits to the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction with outpatient monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antibody increment ≥4 times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Dice scores of auto-delineations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of true GTV structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage change in K1 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: functional connectivity between PAG and MCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to two segment regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Cancer-Related Fatigue (CRF)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: favorable perceptions of cigarillos
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prediction of LNM occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of distant metastasis occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connectivity of higher-order cognitive brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improving nonadherence after ACS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of CBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of CBD and CBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grip strength (paretic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D summary index at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients with Canadian Cardiovascular Class 2 or greater angina at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of younger patients (<65 years old) working at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in prolonged grief disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PES after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBML difference after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chair time required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumor reductions ≥ 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 of intrathecal 2-chloroprocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median pain score during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIII late skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse cosmesis (poor/fair)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coughing incidences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough severities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rates of UFs
Endpoint domain: Mortality/survival
Primary endpoint: Size of recurrent UFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved awareness of mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cold stimulated skin temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint position sense accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in visitor guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ovarian arteries Pulsatility Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: level of anxiety at anesthetic induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median maximum concentration of gilteritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean elimination half-life of gilteritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-QOL total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-5D-5L scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in mood (Change in EPDS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes